Guo-Liang Yu (Ph.D.) is the President, CEO & Chairman of the Board of Epitomics. Biotechnologist and entrepreneur Guo-Liang Yu has more than 12 years of experience in genomics and 24 years of experience in life sciences research.
Yu is a Co-Founder, investor and Board of Director of NVIGEN Inc.
Before cofounding Epitomics, Yu was Senior Vice-President of Research and Development at Mendel Biotechnology Inc. While there, Yu established a robust functional genomics program, exceeded all six milestones for the Research Agreement with Monsanto and Savia, all while managing more than 60 Ph.D. scientists and research associates.
At Human Genome Sciences, Inc., a prominent genomics company, Yu helped to establish the high-throughput gene discovery program. Yu also led the technology development group and cancer group. Yu identified and characterized numerous genes for therapeutic protein and drug discovery.
Yu was a Post-Doctoral Fellow at the Harvard Medical School. Yu holds a Ph.D. degree in Molecular Biology from the University of California, Berkeley and a B.S. degree in Biochemistry from Fudan University, Shanghai, China.
Yu also founded the Chinese Biopharmaceutical Association headquartered in Washington DC. He is coinventor and coauthor of more than 100 patents and scientific articles.
